Regeneron Granted Fundamental Patents Covering Mouse Antibody Technology Used
in VelocImmune® Mice
TARRYTOWN, N.Y., Aug. 7, 2013
TARRYTOWN, N.Y., Aug. 7, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
(NASDAQ: REGN) today announced that the United States Patent and Trademark
Office granted U.S. Patent No. 8,502,018 relating to methods of genetically
modifying a mouse to make human antibodies. A similar European patent, EP 1
360 287 B1, was granted by the European Patent Office on September 12, 2012.
These patents form part of Regeneron's global patent portfolio, which together
protect fundamental inventions behind Regeneron's VelocImmune humanized mice.
The two patents listed above specifically contain claims covering genetically
modified mice that have unrearranged human immunoglobulin variable region gene
segments at endogenous mouse immunoglobulin loci. The VelocImmune mice
contain the full repertoire of human heavy chain immunoglobulin genes and
kappa light chain genes, each linked to endogenous mouse constant regions. As
a result, VelocImmune mice generate a normal and robust immune response which
many believe is becoming the gold standard for making human antibody
therapeutics. VelocImmune is also proving to be one of the most valuable
technologies in biotechnology history, in terms of the licensing and
collaboration revenues it has helped generate.
"VelocImmune provides perhaps the most powerful and efficient way of
generating fully human monoclonal antibodies that are ready for clinical
testing. Its invention has allowed Regeneron to become a leading antibody
therapeutics company, with twelve clinical stage antibodies generated through
our VelocImmune platform currently in clinical development," said George D.
Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President
of Regeneron Laboratories, and a co-inventor of these technologies. "We are
delighted to have been granted these patents covering our inventions, as they
recognize the important advances that we made in this field."
"When Regeneron's VelocImmune mice were developed, they represented the
largest scale precision genetic engineering feat achieved to date," said
Andrew Murphy, Ph.D., Senior Vice President Research, Regeneron Laboratories,
and a co-inventor of these technologies. "The scope of the issued claims in
these two patents reflects the breadth of Regeneron's contribution to human
antibody therapeutics and mouse engineering, and provides Regeneron with
important proprietary technology advantages in the human antibody therapeutic
space both in the United States and Europe."
About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in
Tarrytown, New York that discovers, invents, develops, manufactures, and
commercializes medicines for the treatment of serious medical conditions.
Regeneron markets medicines for eye diseases, colorectal cancer, and a rare
inflammatory condition and has product candidates in development in other
areas of high unmet medical need, including hypercholesterolemia, oncology,
rheumatoid arthritis, allergic asthma, and atopic dermatitis. For additional
information about the company, please visit www.regeneron.com.
Manisha Narasimhan, Ph.D. Peter Dworkin
Investor Relations Corporate Communications
SOURCE Regeneron Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.